Antiviral pharmacology is one of the first topics for Bertin Pharma with first scientific publications concerning HIV in 1991.
Since, in addition to HIV, other in vitro models to evaluate the pharmacological efficacy of candidates against other viruses or pathogens have been developed with the same philosophy:
Likewise, in vivo explorations using animal models of these infections are possible using humanized mice and macaques (Non-Human Primates).
The Life Sciences Division of the CEA, the Institut Pasteur, the Institut National de la Santé et de la Recherche Médicale (INSERM), the Agence Nationale de Recherche sur le SIDA et les Hépatites Virales (ANRS), the Université Paris Sud 11 (UPS-11) and Bertin Pharma have decided to join forces to create a Research Center for Infectious Disease Models and Innovative Therapies (IDMIT) at the CEA site in Fontenay-aux-Roses.
This center is dedicated to translational research programs on innovative human vaccines and antimicrobial treatments.
For information, Microbiological monitoring including virological monitoring of patients enrolled in clinical studies can also be supported by Bertin Pharma in BSL2/BSL3 facilities of its Central Lab.
Moreover, concerning Drug Analysis, the quantification of antimicrobial drugs and their metabolites, particularly for active triphosphorylated metabolites of nucleoside derivatives is possible in all these preclinical & clinical samples.)